Defining normalcy of the somatotropic axis: An attainable goal?

Pituitary

Volumn 10, Issue 2, 2007, Pages 135-139

  Barkan, Ariel L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acromegaly; GH; IGF 1

Indexed keywords

ESTROGEN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; AMENORRHEA; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; BODY GROWTH; BRAIN RADIATION; CLINICAL DECISION MAKING; CYTOREDUCTIVE SURGERY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; MORTALITY; NORMAL VALUE; PITUITARY DWARFISM; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENCE RISK; RELIABILITY; TREATMENT PLANNING;

ACROMEGALY; HEALTH STATUS INDICATORS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; REFERENCE STANDARDS;

EID: 34249880522     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0029-7     Document Type: Article

References (31)

1. Glick AM, Roth J, Yalow RS, Berson SA (1963) Immunoassay of human growth hormone in plasma. Nature 199:784-787
2. Ho PJ, Friberg RD, Barkan AL (1992) Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. J Clin Endocrinol Metab 75(3):812-819
3. Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL (1994) Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 78(6):1403-1410
4. Granada ML, Sanmarti A, Lucas A, Salinas I, Carrascosa A, Foz M, Audi L (1990) Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scand Suppl 379:63-70; discussion 71
5. Christy NP (1982) Choosing the best treatment for acromegaly. JAMA 247(9):1320
6. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA (1993) Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: Outcome analysis and determinants of failure. J Neurosurg 78(2):205-215
7. Bates AS, Van't Hoff W, Jones JM, Clayton RN (1993) An audit of outcomes of treatment in acromegaly. Q J Med 86(5):293-299
8. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95-102
9. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29-41
10. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667-674
11. Barreca A, Ciccarelli E, Minuto R, Bruzzi P, Giordano G, Camanni F (1989) Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh) 120(5):629-635
12. Barkan AL, Beitins IZ, Kelch RP (1998) Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67(1):69-73
13. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91(4):1239-1245
14. Barkan AL (2003) Radiotherapy in acromegaly: The argument against. Clin Endocrinol (Oxf) 58(2):132-135
15. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WL, Barkan AL (2002) Acromegaly with apparently normal GH secretion: Implications for diagnosis and follow-up. J Clin Endocrinol Metab 87(8):3537-3542
16. Desailloud R, Crepin-Hemon S, Simovic-Corroyer B (2005) Acromegaly in elderly people. Ann Endocrinol (Paris) 66(6):540-544
17. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89(2):495-500
18. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: Should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87(7):3142-3147
19. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr D (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52(2):181-185
20. Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, Arosio M (2005) Long-term evaluation of postoperative acromegalic patients in remission with pervious and newly proposed criteria. J Clin Endocrinol Metab 90(3):1377-1382
21. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
22. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after Transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58(1):86-91
23. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW (2003) Long-term treatment outcome in acromegaly. Growth Horm IGF Res 13(4):185-192
24. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301(21):1138-1142
25. Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, Waters MJ (1998) A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-i and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 83:2554-2561
26. Barkan AL, Beitins IZ, Kelch RP (1988) Plasma insulin-like growth factor-1/somatomedin in acromegaly: Correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol. Metab 67:69-73
27. Freda PU (2003) Pitfalls in the biochemical assessment of acromegaly. Pituitary 6(3):135-140
28. Ho KK, O'Sullivan AJ, Wolthers T, Leung KC (2003) Metabolic effects of oestrogens: Impact of the route of administration. Ann Endocrinol (Paris) 64(2):170-7
29. Yakar S, Pennisi P, Wu Y, Zhao H, LeRoith D (2005) Clinical relevance of systemic and local IGF-1. Endocr Dev 9:11-16
30. Isgaard J, Carlsson L, Isaksson OG, Jansson JO. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion
31. Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, van der Lely AJ (2005) The "bio-assay" quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-1 concentrations. Eur J Endocrinol 152(2):217-224